China NMPA Product Recall - Fully Automated Clinical Chemistry Analyzer

On August 7, 2025, Thermo Fisher Scientific (China) Co., Ltd. announced a voluntary Class III recall of the fully automated biochemical analyzer, specifically the Clinical Chemistry Analyzer (National Medical Device Registration Certificate No. 20192221596), manufactured by Thermo Fisher Scientific Oy. This critical action stems from a concerning issue involving the unauthorized installation of third-party software on certain product units. This non-compliant software is identified as a potential cause for interference with the analyzer's normal functionality, leading to compromised product performance and the generation of inaccurate or misleading error messages. The recall highlights the importance of maintaining product integrity and adhering to regulatory standards set by bodies such as the National Medical Products Administration (NMPA). While the document does not specify inspection dates, the company's proactive reporting underscores its commitment to product safety. The regulatory framework requires such medical devices to comply with stringent specifications, which the presence of unauthorized software potentially violates. As a required action, the company has initiated a comprehensive voluntary recall to address these software-related performance discrepancies. Importantly, the affected products were confirmed not to have been imported into the Chinese market, limiting the recall's geographical scope while ensuring patient safety where these devices are in use.